|Day's range||8.64 - 8.81|
|52-week range||7.87 - 10.47|
|PE ratio (TTM)||18.25|
|Earnings date||26 Sep. 2017|
|Dividend & yield||N/A (N/A)|
|1y target est||9.68|
DAVIS, Calif.--(BUSINESSWIRE)-- Marrone Bio Innovations (MBI), Inc. (NASDAQ:MBII - News) and Nufarm Australia Limited announced today the signing of a commercial agreement to develop GRANDEVO® Bioinsecticide, with Nufarm to be the exclusive distributor in Australia and New Zealand (ANZ). Royden Hearn, ANZ Lead Portfolio Solutions at Nufarm said, “We are excited to be working with MBI and see GRANDEVO® as an exciting step forward in integrating biorationals into what we do.
31 October 2016 Australian Securities Exchange Announcement September Quarter Update Highlights: Game changing period for Leaf as it signs JV agreement with leading US- based chemical project developer ...
COMPANY ANNOUNCEMENT 4 October, 2016 Excel Crop Care is an Indian crop protection business, in which Nufarm had an equity accounted 14.69% interest. As advised to the market on 21 September, Nufarm participated ...